The messenger ribonucleic acid (mRNA) technology, proven effective through COVID-19 vaccines, is now opening new avenues in cancer treatment.
A personalized cancer treatment developed jointly by Moderna and Merck (MSD), called Intismeran Autojin (V940), has shown significant improvements in recurrence-free survival and distant metastasis-free survival in a Phase 3 clinical trial involving high-risk melanoma patients. This marks the first time an mRNA-based cancer treatment has yielded positive results in a Phase 3 trial, establishing a milestone in humanity's fight against cancer.
This achievement is noteworthy because it fundamentally alters the approach to attacking cancer. Intismeran analyzes a patient's tumor to identify unique mutations and then delivers information about up to 34 neoantigens via mRNA. This process enables the patient's immune system to learn the characteristics of cancer cells and attack them autonomously, moving away from traditional treatments that administer the same drug to all patients and creating a 'patient-specific therapeutic vaccine.'
The treatment's effectiveness has exceeded initial expectations. Results from a previously announced Phase 2b trial showed that the combination therapy reduced the risk of cancer recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to the monotherapy with Keytruda. The Phase 3 trial included 1,137 patients with stage II to IV melanoma who had undergone surgery, meeting the primary endpoints of recurrence and metastasis suppression. This demonstrates that mRNA technology can extend beyond infectious disease prevention to become a platform for cancer treatment. Moderna and Merck are expanding clinical trials to include lung, bladder, and kidney cancers.
However, it is important to avoid jumping to conclusions about 'conquering cancer.' The announcement has only revealed key results, and specific details on risk reduction are still pending. The overall survival rate, which indicates how much longer patients' lives are extended, also requires further evaluation. Regulatory approvals and long-term safety assessments are still necessary. Since each patient’s tumor must be analyzed and a separate vaccine designed and produced, challenges related to manufacturing time, costs, and quality control must be addressed. If the innovative treatment is priced high, making it accessible only to a select few patients, it would be difficult to claim that medical success translates into social success.
Nonetheless, the significance of this achievement should not be underestimated. mRNA technology can rapidly adapt design and production processes and can be integrated with artificial intelligence, genomic analysis, and immunotherapy techniques. It holds great potential to accelerate the era of precision medicine, where treatment is tailored to patients' genetic characteristics rather than the type of cancer. If the immune system can eliminate residual cancer cells after surgery, preventing recurrence and metastasis, the focus of cancer treatment could shift from extending the lives of terminal patients to early intervention and improving cure rates.
This development presents clear challenges for the South Korean biopharmaceutical industry. Relying solely on vaccine production facilities or contract development and manufacturing capabilities will not suffice to lead the future market. A precision medicine ecosystem that connects tumor sampling, genomic analysis, antigen selection, mRNA design and manufacturing, and hospital administration is essential. The government must clarify standards for utilizing clinical data and protecting genomic information, and expedite the establishment of a regulatory, review, and pricing system suitable for personalized treatments. A foundation for safe data sharing among companies, hospitals, and universities must also be built.
Conquering cancer cannot be achieved by a single company or technology alone. However, the efforts of Moderna and Merck demonstrate that the era of analyzing cancer on a patient-by-patient basis and teaching the immune system how to attack is no longer a fantasy. The spark of mRNA innovation born from the COVID-19 crisis is now leading to hope in cancer treatment. South Korea must focus on accumulating foundational research, clinical trials, data, and manufacturing capabilities with perseverance, rather than chasing short-term results and trends. The path to conquering cancer has been opened. What is now needed is scientific validation, ongoing investment, and a systemic foundation that fairly returns the benefits of innovation to patients.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.